Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Bayer shares up 2.8% in early Frankfurt trade after U.S. Roundup rule

Published 07/16/2019, 03:33 AM
Updated 07/16/2019, 03:33 AM
© Reuters. FILE PHOTO:  Headquarters and main plant of German pharmaceutical and chemical maker Bayer AG in Leverkusen

© Reuters. FILE PHOTO: Headquarters and main plant of German pharmaceutical and chemical maker Bayer AG in Leverkusen

FRANKFURT (Reuters) - Shares in German chemicals company Bayer (DE:BAYGn) rose 1.8% in early trade on Tuesday after a U.S. judge slashed a damages award Bayer owes a California man who blamed its Roundup weed killer for his cancer.

Broker Lang & Schwarz said premarket trades had seen the stock up 4.2%. The stock had fallen 6.5% so far this month.

The judge said evidence against the former Monsanto (NYSE:MON) Co, which Bayer bought last year, supported punitive damages over the glyphosate ingredient contained in Roundup but reduced damages to $20 million from $75 million.

A Frankfurt-based trader said that in his view early Tuesday gains were not sustainable.

"Next Glyphosate trials will start in August," he said. "Bayer will only see an ongoing recovery when it enters mediation talks to settle the 13,400 claims."

Germany's DAX (GDAXI) was 0.06% up.

© Reuters. FILE PHOTO:  Headquarters and main plant of German pharmaceutical and chemical maker Bayer AG in Leverkusen

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.